Crispr Therapeutics Falls on $350M Senior Note Private Placement

Dow Jones03-10

By Elias Schisgall

Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes.

The stock was down 7.3% at $54.49 in Tuesday morning trading. The stock has gained 25% in the past year.

The biopharmaceutical company, which focuses on gene-based medicines, said it plans to sell the convertible senior notes, due 2031, in a private offering to qualified institutional buyers. It said it will use the proceeds for general corporate purposes.

Initial purchasers of the notes will have a 13-day option to buy an additional $52.5 million in senior notes, the company said.

The notes will accrue interest payable on March 1 and Sept. 1 of each year, beginning Sept. 1 2026, and ending March 1, 2031. Notes can also be converted into common shares.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 10, 2026 10:43 ET (14:43 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618516379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 22:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618516379","market":"fut","top_or_hot":-1,"title":"Crispr Therapeutics Falls on $350M Senior Note Private Placement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CRSP\">Crispr</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> were lower after the company said it would raise $350 million through a private offering of senior notes. \n</p>\n<p>\n  The stock was down 7.3% at $54.49 in Tuesday morning trading. The stock has gained 25% in the past year. \n</p>\n<p>\n  The biopharmaceutical company, which focuses on gene-based medicines, said it plans to sell the convertible senior notes, due 2031, in a private offering to qualified institutional buyers. It said it will use the proceeds for general corporate purposes. \n</p>\n<p>\n  Initial purchasers of the notes will have a 13-day option to buy an additional $52.5 million in senior notes, the company said. \n</p>\n<p>\n  The notes will accrue interest payable on March 1 and Sept. 1 of each year, beginning Sept. 1 2026, and ending March 1, 2031. Notes can also be converted into common shares. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2026 10:43 ET (14:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crispr Therapeutics Falls on $350M Senior Note Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrispr Therapeutics Falls on $350M Senior Note Private Placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-10 22:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/CRSP\">Crispr</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> were lower after the company said it would raise $350 million through a private offering of senior notes. \n</p>\n<p>\n  The stock was down 7.3% at $54.49 in Tuesday morning trading. The stock has gained 25% in the past year. \n</p>\n<p>\n  The biopharmaceutical company, which focuses on gene-based medicines, said it plans to sell the convertible senior notes, due 2031, in a private offering to qualified institutional buyers. It said it will use the proceeds for general corporate purposes. \n</p>\n<p>\n  Initial purchasers of the notes will have a 13-day option to buy an additional $52.5 million in senior notes, the company said. \n</p>\n<p>\n  The notes will accrue interest payable on March 1 and Sept. 1 of each year, beginning Sept. 1 2026, and ending March 1, 2031. Notes can also be converted into common shares. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 10, 2026 10:43 ET (14:43 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1861558580.USD","symbol_name":"日兴方舟颠覆性创新基金B","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618516379","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618516379","pubTimestamp":1773153780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes.The stock was down 7.3% at $54.49 in Tuesday morning trading. The stock has gained 25% in the past year.The biopharmaceutical company, which focuses on gene-based medicines, said it plans to sell the convertible senior notes, due 2031, in a private offering to qualified institutional buyers. It said it will use the proceeds for general corporate purposes.Initial purchasers of the notes will have a 13-day option to buy an additional $52.5 million in senior notes, the company said.The notes will accrue interest payable on March 1 and Sept. 1 of each year, beginning Sept. 1 2026, and ending March 1, 2031. Notes can also be converted into common shares.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4539":"次新股","BK4588":"碎股","BK4556":"基因编辑","BK4585":"ETF&股票定投概念","LENZ":"Therapeutics","CRSP":"CRISPR Therapeutics AG","BK4007":"制药","BK4139":"生物科技","BK4611":"AI医疗","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD"},"translate_title":"Crispr Therapeutics因3.5亿美元优先票据私募而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRSP":0.9,"LENZ":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes. \n\n\n  The stock was down 7.3% at $54.49 in Tuesday morning trading. The stock has gained 25% in the past year. \n\n\n  The biopharmaceutical company, which focuses on gene-based medicines, said it plans to sell the convertible senior notes, due 2031, in a private offering to qualified institutional buyers. It said it will use the proceeds for general corporate purposes. \n\n\n  Initial purchasers of the notes will have a 13-day option to buy an additional $52.5 million in senior notes, the company said. \n\n\n  The notes will accrue interest payable on March 1 and Sept. 1 of each year, beginning Sept. 1 2026, and ending March 1, 2031. Notes can also be converted into common shares. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 10, 2026 10:43 ET (14:43 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618516379","isCrawlerRequest":true}